ATE430210T1 - Molekulare diagnose und prognose von karzinomen - Google Patents

Molekulare diagnose und prognose von karzinomen

Info

Publication number
ATE430210T1
ATE430210T1 AT03709296T AT03709296T ATE430210T1 AT E430210 T1 ATE430210 T1 AT E430210T1 AT 03709296 T AT03709296 T AT 03709296T AT 03709296 T AT03709296 T AT 03709296T AT E430210 T1 ATE430210 T1 AT E430210T1
Authority
AT
Austria
Prior art keywords
carcinoma
prognosis
molecular diagnosis
diagnosis
molecular
Prior art date
Application number
AT03709296T
Other languages
English (en)
Inventor
Henri Tiedge
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Application granted granted Critical
Publication of ATE430210T1 publication Critical patent/ATE430210T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03709296T 2002-02-22 2003-02-21 Molekulare diagnose und prognose von karzinomen ATE430210T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35915602P 2002-02-22 2002-02-22
PCT/US2003/005502 WO2003073065A2 (en) 2002-02-22 2003-02-21 Molecular diagnosis and prognosis of carcinomas

Publications (1)

Publication Number Publication Date
ATE430210T1 true ATE430210T1 (de) 2009-05-15

Family

ID=27766045

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03709296T ATE430210T1 (de) 2002-02-22 2003-02-21 Molekulare diagnose und prognose von karzinomen

Country Status (8)

Country Link
US (1) US7510832B2 (de)
EP (1) EP1576349B1 (de)
JP (1) JP4315812B2 (de)
AT (1) ATE430210T1 (de)
AU (1) AU2003213247B2 (de)
CA (1) CA2474700A1 (de)
DE (1) DE60327468D1 (de)
WO (1) WO2003073065A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1578939A4 (de) * 2002-11-12 2007-10-24 Univ New York State Res Found Translationskontrolle durch kleine, nicht translatierbare rnas
CA2872245C (en) * 2012-04-30 2021-08-31 The Research Foundation For Suny Cancer blood test using bc200 rna isolated from peripheral blood for diagnosis and treatment of invasive breast cancer
US9784739B2 (en) 2014-11-10 2017-10-10 The Research Foundation for State University of New York Regulatory brain specific cytoplasmic RNAS (BC RNAs) and methods of use thereof in diagnosis and treatment of neuropsychiatric lupus
CN113604566B (zh) * 2021-07-13 2023-05-16 中山大学孙逸仙纪念医院 lncRNA BCYRN1在膀胱癌预后、治疗中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE335091T1 (de) 1993-05-28 2006-08-15 Sinai School Medicine Bc200 rna, daraus abgeleitete proben und entsprechende anwendungen

Also Published As

Publication number Publication date
US20050164189A1 (en) 2005-07-28
JP2006510870A (ja) 2006-03-30
WO2003073065A2 (en) 2003-09-04
WO2003073065A3 (en) 2006-01-05
EP1576349B1 (de) 2009-04-29
JP4315812B2 (ja) 2009-08-19
AU2003213247A1 (en) 2003-09-09
AU2003213247B2 (en) 2008-06-19
DE60327468D1 (de) 2009-06-10
EP1576349A4 (de) 2006-08-16
US7510832B2 (en) 2009-03-31
CA2474700A1 (en) 2003-09-04
EP1576349A2 (de) 2005-09-21

Similar Documents

Publication Publication Date Title
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
WO2001051628A3 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
CY2010011I2 (el) Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων
CY1108829T1 (el) Ενεργοποιηση ace2 για θεραπεια καρδιακης, πνευμονικης και νεφρικης ασθενειας και υπερτασης
MX2007004176A (es) B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer.
DE69940436D1 (de) Prostata stammzellantigen (psca) und dessen verwendungen
NO20022753D0 (no) Underjordiske formasjonsbehandlingsfluidkonsentrater, behandlingsfluider og fremgangsmåter
DE60335022D1 (de) Internalisierende Antikörper spezifisch für das RAAG10 Zelloberflächenziel
NO20023402D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av prostatakreft
DE60332096D1 (de) Mikrosatellitenmarker in form von mononukleotidwiederholungen zur detektion von mikrosatelliteninstabilität
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
ATE473279T1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
DE602004030890D1 (de) Inhibitoren des extrazellulären hsp90
BRPI0515794A (pt) processos para avaliar pacientes com leucemia mielóide aguda
WO2001018542A3 (en) Identification, assessment, prevention, and therapy of ovarian cancer
DE60327468D1 (de) Molekulare diagnose und prognose von karzinomen
ATE356223T1 (de) Gen und protein mit bezug zu hepatozellulärem karzinom
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
WO2001046697A3 (en) Identification, assessment, prevention, and therapy of breast cancer
ATE410235T1 (de) Behandlung von ballastwasser
WO2002046765A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
Pollack et al. Relationship of tumor DNA-ploidy toserum prostate-specific antigen doubling time after radiotherapy for prostate cancer
WO2004084804A3 (en) Detection and monitoring of lung cancer
WO2002044419A3 (en) Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
DE60212415D1 (de) Die verwendung von einer 4-pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties